VLIYaNIE REFNOTA NA IMMUNITET U ONKOLOGIChESKIKh BOL'NYKh


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

New domestic immunomodulator Refnot is a hybrid molecule of two biologically active agents - tumor necrosis factor α and thymosin α 1. The article presents the results of evaluation of the effect of Refnot in combination with chemotherapy on the main indicators of immunity in patients with metastatic melanoma who had not received drug treatment for the disease dissemination previously. Immunophenotyping of peripheral blood lymphocytes using multiparameter cytometry was performed at different stages of treatment. In combination with chemotherapy, Refnot had a positive impact on the main T-cell populations, as well as on natural killer cells and their cytotoxic activity.

Full Text

Restricted Access

References

  1. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA. 1975;72: 3666-70.
  2. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312:724-29.
  3. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922-33.
  4. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., Harran P., Wang X. Autocrine TNF alpha signaling renders human cancer cells susceptible to Smacmimeticinduced apoptosis. Cancer Cell. 2007;12:45-56.
  5. Wang X., Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol. Sin. 2008;29( 11 ):1275-88.
  6. Славина Е.Г., Бигвава Х.А., Заботина Т.Н., Борунова Т.Н., Морозова Л.Ф., Черткова А.И., Нуртдинова В.А., Кадагидзе З.Г. Модификация фактором некроза опухоли (ФНО-α) цитотоксического и апоптотического действия противоопухолевых лекарств в клетках меланомы человека. Российский биотерапевтический журнал. 2009;8(4):37-44.
  7. Alexander H.R.Jr, Bartlett D.L., Libutti S.K., Pingpank J.F., Fraker D.L., Royal R., Steinberg S.M., Helsabeck C.B., Beresneva T.H. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann. Surg. Oncol. 2009;16(7):1852-59.
  8. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., Hariri R.J., Fahey T.J., Zentella A., Albert J.D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-74.
  9. Tracey K.J., Wei H., Manogue K.R., Fong Y., Hesse D.G., Nguyen H.T., Kuo G.C., Beutler B., Cotran R.S., Cerami A., Lowry S.F. Cachectin/ tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 1988;167:1211-27.
  10. Grünhagen D.J., de Wilt J.H., van Geel A.N., Verhoef C., Eggermont A.M. Isolated limb perfusion with TNF-α and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res. 2009;179:257-70.
  11. Deroose J.P., Grünhagen D.J., van Geel A.N., de Wilt J.H., Eggermont A.M., Verhoef C. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases. Br. J. Surg. 2011;98:1573-80.
  12. Goldstein A.L., Guha A., Zatz M.M., Hardy M.A., White A. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc. Natl. Acad. Sci. USA 1972;69: 1800-03.
  13. Romani L., Moretti S., Fallarino F., Bozza S., Ruggeri L., Casagrande A., Aversa F., Bistoni F., Velardi A., Garaci E. Jack of all trades: thymosin α1 and its pleiotropy. Ann. N.Y. Acad. Sci.2012;1269:1-6.
  14. King R.S., Tuthill C. Evaluation of thymosin alpha 1 (Ta1) in nonclinical models of the immune-suppressing indications melanoma and sepsis. Expert. Opin. Biol. Ther. 2015;2:1-9.
  15. Maio M., Mackiewicz A., TestoriA., Trefzer U., Ferraresi V., Jassem J., Garbe C., Lesimple T., Guillot B., Gascon P., Gilde K., Camerini R., Cognetti F. Thymosin Melanoma Investigation Group. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 2010;28( 10):1 78-87.
  16. Garaci E., Favalli C., Pica F., Sinibaldi Vallebona P.,Palamara A.T., Matteucci C., Pierimarchi P., Serafino A., Mastino A., Bistoni F., Romani L., Rasi G. Thymosin alpha 1: from bench to bedside. Ann. N.Y. Acad. Sci. 2007;1112:225-34.
  17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assayю J. Immunol. Meth. 1983;65:55-63.
  18. Кадгидзе З.Г., Славина Е.Г., Абрамов М.Е., Вышинская Г.В., Даренская А.Д. Новый иммуномодулятор Рефнот в лечении онкологических больных. Фарматека. 2013;8:71-74.
  19. Dai S.X., Wu G., Zou Y. Feng Y.L., Liu H.B., Feng J.S., Chi H.G., Lv R.X., Zheng X.B. Balance of CD8+CD28+/CD8+CD28-T lymphocytes is vital for patients with ulcerative colitis. Dig. Dis. Sci. 2013; 58:88-96.
  20. LiX., Kong H., TianL.,ZhuQ., WangY., DongY., Ni Q., Chen Y. Changes of costimulatory molecule CD28 on circulating CD8+ T cells correlate with disease pathogenesis of chronic hepatitis B. Biomed. Res. Int. 2014; 2014:423181.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies